Video Library

Neuropathy (nerve damage) sometimes occurs after a stem cell transplant. It most often affects hands and feet but can affect other parts of the body as well. This presentation explains what causes neuropathy after transplant and various treatments available to relieve it.

Graft-versus-host-disease (GVHD) can cause physical problems that interfere with a person's ability to manage daily tasks. Physical Medicine and Rehabilitation (PM&R) physicians, also known as physiatrists, can diagnose why a person is experiencing pain or decreased physical functioning and direct them to the correct specialist to address these problems.

Chronic graft-versus-host disease (GVHD) can make it difficult to perform many daily activities. This video demonstrates various exercises to improve flexibility and strength, as well as some adaptive devices that can make it easier to do routine daily activities by yourself. Download the speaker slides for printed instructions and illustrations of the exercises and devices demonstrated in the video.

La enfermedad de injerto contra huésped (EICH) es una complicación común después de un trasplante que utiliza células de un donante (trasplante alogénico). Hay dos tipos diferentes de EICH que difieren en los órganos que afectan y en el momento en que se desarrollan normalmente. Esta presentación analiza las causas de la EICH, cómo afecta a varios órganos y las opciones de tratamiento.

There are several safe and effective vaccines for COVID-19. These vaccines are recommended for transplant patients in most circumstances. This presentation reviews guidelines, offers recommendations, and answers questions about the benefits of COVID-19 vaccines for transplant patients.

Myelodysplastic syndrome (MDS) is a blood disorder that can develop into leukemia. There are several treatments for MDS, including stem cell transplantation. This presentation reviews key features of MDS, treatment options and when a transplant is an appropriate remedy.

Acute myeloid leukemia (AML) is a blood cancer that has been historically challenging to treat. It often requires a bone marrow or stem cell transplant that can be curative but brings significant risks and side effects. However, new drugs and clinical trials have expanded treatment options and moderated side effects for many patients.

CAR T cell therapy is a new type of therapy for patients with multiple myeloma. It is currently available for patients who have relapsed after four or more rounds prior therapy. This presentation describes CAR T cell and related therapies as well as new drugs in the pipeline to treat patients with multiple myeloma

Anxiety and depression are common among cancer patients and survivors. Acceptance and commitment therapy is an effective tool for these problems. This presentation discusses the mental health challenges of transplant and GVHD patients and how this therapy can help them.

Sickle cell disease disproportionately affects African Americans. However, stem cell transplants and gene therapy offer promising treatment options. This presentation describes these treatments, their outcomes, and which treatments are appropriate for which patients.

The number of long-term survivors of hematopoietic cell transplants (bone marrow, stem cell, and cord blood) is dramatically increasing. However, up to two thirds of survivors report at least one chronic health condition as a late effect of treatment. This presentation describes these effects and interventions to treat them.

Autologous stem cell transplants use the patient’s own stem cells to rescue him or her from the effects of high-dose chemotherapy. This type of transplant is most often used to treat patients with multiple myeloma, non-Hodgkin lymphoma and Hodgkin lymphoma. This presentation discusses the transplant process, and common early and late complications.